AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-16322071_ITM" title="Facts and information about GW Pharmaceuticals begins second pivotal Phase III trial of MS drug Sativex.">GW Pharmaceuticals begins second pivotal Phase III trial of MS drug Sativex.</a>
Close
Set up an RSS feed that alerts you when new articles from Europe Intelligence Wire are available.
Frequently asked questions about RSS feeds
GW Pharmaceuticals begins second pivotal Phase III trial of MS drug Sativex.
(From AFX UK (Focus))
LONDON (AFX) - GW Pharmaceuticals PLC said it has begun a second pivotal Phase III trial of Sativex as a treatment for pain associated with multiple sclerosis.
The company said the study aims to determine the efficacy of Sativex as a treatment for patients with central neuropathic pain resulting from MS, with the headline results expected in about a year.
GW …
Related articles from newspapers, magazines, journals, and more
-
- AFX NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 09:10 BST.
-
News wire article from: Europe Intelligence Wire
September 5, 2006
700+ words
-
- AFX NEWS BRIEFING: Pharmaceuticals and chemicals highlights to 15:40 BST.
-
News wire article from: Europe Intelligence Wire
September 21, 2006
700+ words
-
- Schwarz Pharma says initial phase III Rotigotine trial successful.
-
News wire article from: Europe Intelligence Wire
October 9, 2006
700+ words
-
- GlaxoSmithKline, Human Genome Sciences start Phase III trial on lupus drug.
-
News wire article from: Europe Intelligence Wire
February 13, 2007
700+ words
-
- Oxford BioMedica starts TroVax Phase III trial, still sees to market in 2009.
-
News wire article from: Europe Intelligence Wire
November 7, 2006
700+ words
